Bio-Matrix Scientific's Research Subsidiary, Entest BioMedical, Inc., Files Stem Cell Therapy Patent Application For Treatment Of COPD

Main Category: COPD
Also Included In: Stem Cell Research
Article Date: 21 Aug 2009 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced its majority owned subsidiary, Entest BioMedical unit (OTCBB: ENTB), has filed a patent application for the use of adipose derived stem cells in the treatment of Chronic Obstructive Pulmonary Disease (COPD). BMSN is excited with the progress achieved by Entest BioMedical, Inc. (OTCBB: ENTB) in identifying diseases it believes will be treatable through Stem Cell Therapy.

Chronic Obstructive Pulmonary Disease is a major health disorder that appears to be treatable through adipose derived stem cell therapy. COPD is a group of lung inflammatory diseases which includes both emphysema and chronic obstructive bronchitis affecting more than 5 million Americans each year. It is the fourth leading cause of death in America, impacting more than 5 million Americans, resulting in more than 120,000 deaths in the USA per year.

Currently, this disease is treated in similar fashion to asthma, utilizing inhalers and /or oxygen therapy. These methods are not solutions to the disease but merely provide the patient with greater level of comfort.

Steven Josephs, PhD. noted, "The approach is intended at the very least to alleviate the chronic inflammation in COPD. This is done by using agents known to coax adult stem cells that are delivered to the diseased lung tissue (blood monocyte cells) to release cytokines (biologically active molecules) which in addition to the anti-inflammatory effects may actually promote the regeneration of functional lung tissue."

The goal of Entest BioMedical, Inc. is to develop a stem cell therapy that reverses the effects of COPD on the respiratory system. The Company is working with Dr. Feng Lin, its Scientific Director and Steven Josephs, PhD in developing this stem cell treatment.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

Source
Entest BioMedical Inc.